|Report Code: PP10180||Report Type: Molecule-Type Pipeline Reports||Available format:|
Biosimilar are biological products that show similar biological action as the U.S. Food and Drug Administration (USFDA) approved biologics. According to the U.S. Federal Code of Regulation, the biologic is a virus, toxin, antitoxin, or therapeutic serum valid for the treatment of a disease. Biosimilars become a potential cost-saving alternative and provide the similar effects as biologics, thus, are being prescribed with confidence. M923 of Momenta Pharmaceuticals Inc. is a proposed adalimumab biosimilar for the treatment of plaque psoriasis. Biocon Ltd. is also developing a wide portfolio of monoclonal antibody biosimilars for the treatment of cancer, diabetes, and rheumatoid arthritis.
Novartis AG is developing GP2018 for the treatment of autoimmune diseases, such as rheumatoid arthritis and psoriasis. Samsung Bioepis Co. Ltd. has a robust biosimilar pipeline and is developing two major biosimilars, which are currently in the Phase III stage of development, including SB8 (bevacizumab biosimilar) for the treatment of non-small lung cancer, and SB11 (ranibizumab biosimilar) for the treatment of age-related macular degeneration. Some other companies having the pipeline of biosimilars include Biogen Inc., and Celltrion Inc. among others.